Drug Profile
Research programme: autoimmune disease fat stem cell therapies - Precigen Inc
Alternative Names: Fat stem cell therapy - Precigen IncLatest Information Update: 10 Feb 2020
Price :
$50
*
At a glance
- Originator MediStem Laboratories
- Developer Precigen Inc
- Class Stem cell therapies
- Mechanism of Action Cell replacements; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Autoimmune disorders
Most Recent Events
- 03 Feb 2020 Intrexon Corporation is now called Precigen Inc
- 16 Jul 2016 No recent reports of development identified for preclinical development in Autoimmune-disorders in USA (Parenteral)
- 07 Mar 2014 Medistem has been acquired by Intrexon Corporation